Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

被引：8
|
作者：
Slade, Michael [1 ]
Martin, Thomas G. [2 ]
Nathwani, Nitya [3 ]
Fiala, Mark A. [1 ]
Rettig, Michael P. [1 ]
Gao, Feng [1 ]
Deol, Abhinav [4 ]
Buadi, Francis K. [5 ]
Kaufman, Jonathan L. [6 ]
Hofmeister, Craig C. [6 ]
Gregory, Tara K. [7 ]
Berdeja, Jesus [8 ]
Chari, Ajai [9 ]
Rosko, Ashley [10 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63130 USA
[2] Univ Calif San Francisco, San Francisco, CA USA
[3] City Hope Comprehens Canc Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Mayo Clin, Rochester, MN USA
[6] Emory Univ, Atlanta, GA USA
[7] Sarah Cannon Res Inst, Denver, CO USA
[8] Sarah Cannon Res Inst, Nashville, TN USA
[9] Icahn Sch Med Mt Sinai, New York, NY USA
[10] Ohio State Univ, Columbus, OH 43210 USA
来源：
LEUKEMIA | 2022年 / 36卷 / 12期
基金：
美国国家卫生研究院;
关键词：
STEM-CELL TRANSPLANTATION; ORAL IXAZOMIB; BORTEZOMIB;
D O I：
10.1038/s41375-022-01691-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2917 / 2921
页数：5
相关论文
共 50 条
  • [1] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
    Michael Slade
    Thomas G. Martin
    Nitya Nathwani
    Mark A. Fiala
    Michael P. Rettig
    Feng Gao
    Abhinav Deol
    Francis K. Buadi
    Jonathan L. Kaufman
    Craig C. Hofmeister
    Tara K. Gregory
    Jesus Berdeja
    Ajai Chari
    Ashley Rosko
    Ravi Vij
    [J]. Leukemia, 2022, 36 : 2917 - 2921
  • [2] Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Phuong-Dung, Liang
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Malave, Gabriella C.
    Vossen, Alanna M.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    [J]. BLOOD, 2020, 136
  • [3] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    [J]. BLOOD, 2021, 137 (26) : 3616 - 3628
  • [4] Alternating the Administration of Ixazomib and Lenalidomide As Maintenance Therapy after Autologous Transplant for Multiple Myeloma
    Holmberg, Leona A.
    Green, Damian J.
    Lee, Sarah S.
    Cowan, Andrew J.
    [J]. BLOOD, 2022, 140 : 10575 - 10576
  • [5] Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial
    Vij, Ravi
    Martin, Thomas G., III
    Nathwani, Nitya
    Fiala, Mark A.
    Gao, Feng
    Deol, Abhinav
    Buadi, Francis K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Gregory, Tara K.
    Berdeja, Jesus G.
    Chari, Ajai
    Rosko, Ashley E.
    [J]. BLOOD, 2019, 134
  • [6] Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
    Moreau, P.
    Masszi, T.
    Grzasko, N.
    Bahlis, N. J.
    Hansson, M.
    Pour, L.
    Sandhu, I.
    Ganly, P.
    Baker, B. W.
    Jackson, S. R.
    Stoppa, A. -M.
    Simpson, D. R.
    Gimsing, P.
    Palumbo, A.
    Garderet, L.
    Cavo, M.
    Kumar, S.
    Touzeau, C.
    Buadi, F. K.
    Laubach, J. P.
    Berg, D. T.
    Lin, J.
    Di Bacco, A.
    Hui, A. -M.
    van de Velde, H.
    Richardson, P. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (17): : 1621 - 1634
  • [7] Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone
    Huo, Zhongjun
    Chen, Fang
    Liu, Ping
    Luo, Zimian
    [J]. CANCER MEDICINE, 2023, 12 (03): : 2937 - 2944
  • [8] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
    Shaji K. Kumar
    Jesus G. Berdeja
    Ruben Niesvizky
    Sagar Lonial
    Jacob P. Laubach
    Mehdi Hamadani
    A. Keith Stewart
    Parameswaran Hari
    Vivek Roy
    Robert Vescio
    Jonathan L. Kaufman
    Deborah Berg
    Eileen Liao
    S. Vincent Rajkumar
    Paul G. Richardson
    [J]. Leukemia, 2019, 33 : 1736 - 1746
  • [9] Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
    Kumar, Shaji K.
    Berdeja, Jesus G.
    Niesvizky, Ruben
    Lonial, Sagar
    Laubach, Jacob P.
    Hamadani, Mehdi
    Stewart, A. Keith
    Hari, Parameswaran
    Roy, Vivek
    Vescio, Robert
    Kaufman, Jonathan L.
    Berg, Deborah
    Liao, Eileen
    Rajkumar, S. Vincent
    Richardson, Paul G.
    [J]. LEUKEMIA, 2019, 33 (07) : 1736 - 1746
  • [10] Ixazomib and lenalidomide maintenance therapy in multiple myeloma
    Parrondo, Ricardo D.
    Alegria, Victoria
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (03) : 851 - 853
12345